

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	23
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	40
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	44
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	47
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Lithuania (Eastern Europe)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.16	0.22	0.29
Year of IDU prevalence estimate	2006		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	0.06	2.4	4.77
Year of HIV prevalence among IDU estimate	2003		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age in 2008	2 283 199 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	3500	5000	6500
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	2	120	310

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2007
Reference	See references for other NSP indicators
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

NSP 2: Number of NSP sites

Data reported	10 sites (12 fixed sites 5 outreach workers sites 2 mobile sites)		
Year of reported data	2008 2007		
Reference	World Health Organisation (2009). Global health ATLAS data. European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments	- Assumed counts of all site are mutually exclusive. Total number Of sites calculated.		
Final/Adjusted data (to be used as indicator numerator)	10 - 19		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	1.54	2.90	5.43

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	3399 individual clients (an estimate)		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3399		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	52.3	68.0	97.1

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	43 856 client contacts An estimate		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	43 856		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	6.75	8.77	12.53

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	187 227 syringes provided through needle and syringe programmes		
Year of reported data	2007		
Reference	<p>European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr.</p> <p>Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.</p> <p>Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.</p> <p>Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use.</p> <p>WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	187 227		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	28.80	37.4	53.49

NSP: All documents reviewed

Aceijas, C., M. Hickman, et al. (2007). "Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia.[see comment]." *Addiction* 102(8): 1244-50.

Alban, A. and J. Kutzin (2006). *Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications*, World Health Organization: 47.

Caplinskiene, I., A. Griskevicius, et al. (2004). "Research of drug use and biological markers in the clients of the Harm Reduction Site at the Lithuanian AIDS Centre."

Central and Eastern European Harm Reduction Network (2007). *Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations*.

Drew, R. (2009). *Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania*.

Eurasian Harm Reduction Network (2007). *Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations*. Vilnius, Central and Eastern European Harm Reduction Network,.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." *Statistical Bulletin* Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." *Statistical Bulletin* 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). *Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007*.

Islam, M. M. and K. Conigrave (2007). "Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): a review." *Harm Reduction Journal* 4(1): 14.

Juodkaite, D. and R. Uscila (2008). *Lithuanian legislation and policy analysis on HIV/AIDS and care among injecting drug users in prison settings*, United Nations Office on Drugs and Crime (UNODC).

Reitox National Focal Point (2008). *Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA*.

Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. *Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania"*. Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and

WHO and UNAIDS (2008). *Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia* WHO.

WHO, UNAIDS., et al. (2009). *Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009*. Geneva, WHO.

World Health Organisation (2009). *Global health ATLAS data*.

2. Opioid substitution treatment (OST)

OST 1: Availability of opioid substitution treatment (OST)

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other OST indicators
When was agonist OST first available?	1996
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other OST indicators
When was MMT first available?	1996
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2008
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use
When was BMT first available?	2002
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA. European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	14 OST sites 16 MMT sites 2 BMT sites not known		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments	Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	14 - 18		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	2.15	3.20	5.14

OST 8: Number of sites providing MMT

Data reported	16 MMT sites		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	16		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	2.46	3.20	4.57

OST 9: Number of sites providing BMT

Data reported	2 BMT sites		
Year of reported data	2009		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	2		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 264 376 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	0.31	0.40	0.57

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	486 clients in MMT 26 clients in BMT		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments	Assumed counts are mutually exclusive Assumed enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	512		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	7.88	10.24	14.63

OST 12: Number of all clients in MMT at a single point in time

Data reported	486 clients receiving MMT in Dec 2008 nationally		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments	Assumed count equals enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	486		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	7.48	9.72	13.89

OST 13: Number of all clients in BMT at a single point in time

Data reported	26 clients receiving BMT in Dec 2008 nationally		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments	Assumed count equals enrolment at a census date		
Final/Adjusted data (to be used as indicator numerator)	26		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	0.40	0.52	0.74

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	OST available but number of clients on OST not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	MMT available but number of clients not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2008		
Reference	Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

Alban, A. and J. Kutzin (2006). Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications, World Health Organization: 47.

Caplinskiene, I., A. Griskevicius, et al. (2004). "Research of drug use and biological markers in the clients of the Harm Reduction Site at the Lithuanian AIDS Centre."

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." *International Journal of Drug Policy* 18(4): 271-80.

Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Eurasian Harm Reduction Network, ECCB, et al. (2008). Substitution therapy in 9 countries in Eastern Europe and Central Asia.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." *Statistical Bulletin* Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." *Statistical Bulletin* 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

International AIDS Society (2008). Expanding access to opioid substitution therapy for injecting drug users in Eastern Europe and Central Asia. IAS Yalta Scientific Leadership Summit.

International AIDS Society (2008). Opioid substitution therapy in selected countries of East European and Central Asia.

Juodkaite, D. and R. Uscila (2008). Lithuanian legislation and policy analysis on HIV/AIDS and care among injecting drug users in prison settings., United Nations Office on Drugs and Crime (UNODC).

Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

Rotberga, S. (Regional Project Coordinator), UNODC Project Office for the Baltic States. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - Lithuania". Vilnius, Lithuania, 2009. Received by the Reference Group to the UN on HIV and

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	Detoxification available but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?	Yes		
Number of sites - data reported	17 centres of long-term rehabilitation		
Year of reported data	2007		
Reference	Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	17		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	2.62	3.40	4.86

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2007		
Reference	Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.: Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.: Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychosocial support and counselling present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.: Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	23 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	23		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	3.54	4.60	6.57

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	Out-patient treatment - type not specified		
Number of sites - data reported	196 outpatient units inpatient units not reported		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	>=196		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	30.15	39.20	56

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	5715 clients entering treatment at 90 out of 196 outpatient treatment units reporting data 92.8% of clients entering treatment injected primary drug		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	For lower bound included data on clients entering treatment only from sites reporting data For upper bound assumed average number clients accessing services per site for sites reporting data is the same as for sites for which data were not reported Number of IDUs in treatment calculated		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	5304 - 11 550		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	81.60	168.54	330
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	5715 clients entering treatment at 90 out of 196 outpatient treatment units reporting data		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	For lower bound included data on clients entering treatment only from sites reporting data For upper bound assumed average number clients accessing services per site for sites reporting data is the same as for sites for which data were not reported		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	5715 - 12 446		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	0.88	1.82	3.56
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Alban, A. and J. Kutzin (2006). Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications, World Health Organization: 47.

European monitoring Centre for Drugs and Drug Addiction. (2008). "Treatment demand indicator - Statistical bulletin " Statistical Bulletin Retrieved 6 April, 2009, from http://www.emcdda.europa.eu/html.cfm/index65250EN.html?type=stats&stat_category=w100&stat_type=w87&order=stat_reference&CFID=5203606&CFTOKEN=161d43f9a7fd61fb-2D894FE8-E64D-EF3F-72C0BF31D6EAF23A&jsessionid=3830aef6e3d5cdb788212d644b714373741b.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/tdi>.

Expanding Network for Coordinated and Comprehensive Actions on HIV/AIDS Prevention among IDUs and Bridging Population (2009). Prevalence of HIV and other infections and risk behaviour among injecting drug users in Latvia, Lithuania and Estonia in 2007.

Reitox National Focal Point (2008). Lithuania - New Development, Trends and in-depth information on selected issues. 2008 National report (2007 data) to the EMCDDA.

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2009
Reference	Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania. Juodkaite, D. and R. Uscila (2008). Lithuanian legislation and policy analysis on HIV/AIDS and care among injecting drug users in prison settings., United Nations Office on Drugs and Crime (UNODC).

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2009		
Reference	Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania. Juodkaite, D. and R. Uscila (2008). Lithuanian legislation and policy analysis on HIV/AIDS and care among injecting drug users in prison settings., United Nations Office on Drugs and Crime (UNODC).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 264 376 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2008
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.
Data reported for both male and female IDUs	67% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	67%
Data reported for male IDUs	60% male IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	60%
Data reported for female IDUs	81% female IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	81%

T&C: All documents reviewed

Alban, A. and J. Kutzin (2006). Scaling up treatment and care for HIV/AIDS and TB and accelerating prevention within the health system in the Baltic States (Estonia, Latvia, Lithuania): Economic, health financing and health system implications, World Health Organization: 47.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.

Juodkaite, D. and R. Uscila (2008). Lithuanian legislation and policy analysis on HIV/AIDS and care among injecting drug users in prison settings., United Nations Office on Drugs and Crime (UNODC).

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	7 sites		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	7		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 283 199 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
HIV among IDU prevalence estimate (%)	Low	Mid	High
	0.06	2.40	4.77
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	2	120	310
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	1.08	1.40	2
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	22.59	58.33	3116.37

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	6 IDUs on OST are on ART. These 6 IDUs represent 32% of all IDUs on ART		
Year of reported data	2006		
Reference	WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.		
Adjustments	Calculated the total number of IDUs on ART		
Final/Adjusted data (to be used as indicator numerator)	19		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 314 503 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
HIV among IDU prevalence estimate (%)	Low	Mid	High
	0.06	2.40	4.77
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	2	120	310
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	6.13	15.83	845.87

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." *International Journal of Drug Policy* 18(4): 271-80.

Drew, R. (2009). Mid-term evaluation of unodc project XEEJ20 - HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania.

European AIDS Treatment Group (2008). Antiretroviral treatment for injecting drug users in Central and Eastern Europe.

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	Condoms are distributed at low threshold NSP facilities.
Year	2007
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	NK	NK	NK

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2007		
Reference	Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.16	0.22	0.29
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	2 300 755 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	3500	5000	6500
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

Central and Eastern European Harm Reduction Network (2007). Hepatitis C among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations.

Eurasian Harm Reduction Network (2007). Hepatitis C among Injecting Drug Users in the New EU Member States and Neighboring Countries: Situation, Guidelines and Recommendations. Vilnius, Central and Eastern European Harm Reduction Network,.

Juodkaite, D. and R. Uscila (2008). Lithuanian legislation and policy analysis on HIV/AIDS and care among injecting drug users in prison settings., United Nations Office on Drugs and Crime (UNODC).